Zynex (NASDAQ:ZYXI) shares are trading lower on Monday after the company cut its third-quarter sales guidance below analyst estimates.
Zynex is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The company designs, manufacture, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation.
Zynex shares traded down 25.90% to $14.62 on Monday at the time of publication. The stock has a 52-week high of $29.73 and a 52-week low of $7.51.